AL
Live price temporarily unavailable.
Price history
Aligos Therapeutics (ALGS) is a Health Care company. Latest news and coverage below.
IPO: October 16, 2020 · $15.00 offering · NASDAQ · View IPO details →
Aligos Therapeutics revenue & net income history (FY2019–FY2025)
RevenueNet income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | $0 | $0 | $0 | $6.19M | $3.61M | $2.19M |
| Growth (year over year) | — | — | — | — | — | −41.7% | −39.5% |
| Operating income | −$54.0M | −$97.8M | −$128.3M | −$97.6M | −$88.1M | −$89.2M | −$88.0M |
| Operating margin | — | — | — | — | −1423.5% | −2469.0% | −4024.9% |
| Net income | −$52.3M | −$108.5M | −$128.3M | −$96.0M | −$87.7M | −$131.2M | −$24.2M |
| Net margin | — | — | — | — | −1416.2% | −3633.6% | −1106.7% |
| EPS (diluted) | −$16275.00 | −$6793.75 | −$2012.50 | −$56.25 | −$34.20 | −$20.94 | −$2.45 |
| Balance sheet | |||||||
| Cash and equivalents | $69.6M | $220.4M | $186.8M | $81.3M | $135.7M | $37.0M | $18.3M |
| Total assets | $146.5M | $265.3M | $235.4M | $146.7M | $151.5M | $70.1M | $88.5M |
| Total liabilities | $29.3M | $45.3M | $50.6M | $42.8M | $59.4M | $99.1M | $35.0M |
| Shareholders' equity | −$64.9M | $220.0M | $184.7M | $103.9M | $92.1M | −$29.0M | $53.5M |
| Cash flow | |||||||
| Operating cash flow | −$46.8M | −$74.3M | −$115.7M | −$79.4M | −$79.0M | −$80.7M | −$82.5M |
| Capital expenditure | $2.79M | $2.06M | $892.0K | $943.0K | $19.0K | $130.0K | — |
| Free cash flow | −$49.6M | −$76.3M | −$116.6M | −$80.3M | −$79.0M | −$80.9M | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.25M | $606.0K | $311.0K | $965.0K | $741.0K | — | $2.83M | $0 |
| Growth (year over year) | +15.2% | −9.8% | −55.2% | −9.0% | −40.7% | — | +810.0% | −100.0% |
| Operating income | −$20.1M | −$20.6M | −$19.2M | −$18.6M | −$28.4M | — | −$26.9M | −$1.89M |
| Operating margin | −1610.5% | −3393.2% | −6187.5% | −1924.0% | −3827.4% | — | −951.6% | — |
| Net income | −$19.3M | −$82.2M | $43.1M | −$15.9M | −$31.5M | — | −$23.0M | −$1.50M |
| Net margin | −1540.7% | −13556.1% | 13854.7% | −1643.8% | −4256.0% | — | −814.1% | — |
| EPS (diluted) | −$3.07 | −$13.10 | −$2.11 | −$1.53 | −$3.04 | — | −$2.21 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $35.3M | $37.0M | $73.8M | $18.7M | $41.9M | $18.3M | $30.0M | $30.4M |
| Total assets | $88.4M | $70.1M | $150.7M | $134.7M | $109.8M | $88.5M | $64.6M | $66.3M |
| Total liabilities | $38.3M | $99.1M | $34.3M | $32.8M | $37.9M | $35.0M | $32.8M | $34.4M |
| Shareholders' equity | $50.1M | −$29.0M | $116.4M | $101.9M | $71.8M | $53.5M | $31.8M | $31.9M |
| Cash flow | ||||||||
| Operating cash flow | −$20.1M | −$18.4M | −$20.9M | −$15.5M | −$24.3M | — | −$23.1M | −$24.9M |
From Aligos Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Aligos Therapeutics
- Headquarters
- South San Francisco, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International